PRINCETON, N.J., June 27 /PRNewswire/ -- Lisa Flood, BSN, has joined Agile Therapeutics Inc as Associate Director of Regulatory and Quality Assurance. Ms. Flood received her Bachelor of Science Nursing degree from Rutgers University College of Nursing in 1997, and has worked in both large and small company settings, most recently as Senior Manager of Clinical Research at Valera Pharmaceuticals. Her experience includes development of standard operating procedures, regulatory submissions, and clinical operations.
Agile Therapeutics is an emerging bio-pharmaceutical company focused on developing the next generation of transdermal contraception, a low estrogen dose patch, which is now in Phase II clinical trials.
"I'm greatly pleased to have Lisa joining the Agile Therapeutics development team," said CEO Thomas M. Rossi, Ph.D. "She greatly enhances our ability to develop and execute a successful clinical and regulatory strategy as we advance our new generation of low-dose transdermal contraceptives further through the Phase II clinical trials process and as we examine opportunities to extend our women's health care development pipeline."
Agile Therapeutics' lead product is a second generation transdermal contraceptive patch, designed to be worn for seven days for three consecutive applications during a monthly cycle. The product utilizes a patented formulation technology to deliver a combination of levonorgestrel and a low dose of ethinyl estradiol.
About Agile Therapeutics
Agile Therapeutics is a privately funded women's health company focused on developing the next generation of low-dose transdermal contraceptives. Agile's patch is expected to effectively compete in the $5 billion worldwide contraceptive market and is currently in Phase II clinical development. The Company is supported by high-quality health care investors, including ProQuest, a healthcare venture capital firm that is managing over $875 million; the Hillman Company and its Affiliates, a diversified investment firm active in venture capital investing for over 25 years; TL Ventures, with over $1.4 billion under management; and PA Early Stage Partners, with more than $235 million under management.
Agile Therapeutics IncCONTACT: Steve Ross for Agile Therapeutics Inc, +1-908-507-7335
Web site: http://www.agiletherapeutics.com/
